scholarly journals The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes

2018 ◽  
Vol 22 (8) ◽  
pp. e13287
Author(s):  
Vanessa Fabrizio ◽  
Amy Wahlquist ◽  
Elise Hill ◽  
Elizabeth Williams ◽  
Cindy Kramer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Marrow Graft ◽  
Bone Marrow Graft ◽  
Transplantation Outcomes ◽  
Graft Composition

scholarly journals The Effect of Bone Marrow Graft Composition on Pediatric Bone Marrow Transplantation Outcomes

2016 ◽  
Vol 22 (3) ◽  
pp. S247-S248
Author(s):  
Vanessa Fabrizio ◽  
Amy Wahlquist ◽  
Elsie Hill ◽  
Elizabeth J. Williams ◽  
Cindy Kramer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Marrow Graft ◽  
Bone Marrow Graft ◽  
Transplantation Outcomes ◽  
Graft Composition

Subtyping of erythrocyte phosphoglucomutase-1 as a genetic marker for bone-marrow engraftment and hematopoietic chimerism after allogeneic bone-marrow transplantation in a patient with acute lymphoblastic leukemia.

1988 ◽  
Vol 34 (12) ◽  
pp. 2586-2588 ◽  
Author(s):  
B Grahovac ◽  
B Labar ◽  
A Stavijenić
Keyword(s):  
Bone Marrow ◽  
Acute Lymphoblastic Leukemia ◽  
Bone Marrow Transplantation ◽  
Genetic Marker ◽  
Marrow Transplantation ◽  
Lymphoblastic Leukemia ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Marrow Graft

Abstract We report an effective follow-up of the establishment of bone-marrow function after an allogeneic bone-marrow transplantation in a patient with acute lymphoblastic leukemia, by means of a suitable genetic marker, phosphoglucomutase-1 (EC 5.4.2.2) isoenzyme. A patient with acute lymphoblastic leukemia received allogeneic bone-marrow graft from a sibling who was of the same sex and blood group, HLA-identical, and mixed-lymphocyte-culture nonreactive. To monitor the bone-marrow engraftment and the type and degree of chimerism established, we used a genetic marker, the phosphoglucomutase-1 isoenzyme system, to reveal the difference between the bone-marrow host and donor. We did phosphoglucomutase-1 isoenzyme subtyping of the host's and donor's erythrocytes before transplantation, and isoenzyme phenotyping of the host's erythrocytes during a year after transplantation. Establishment of bone-marrow graft function, a period of temporary mixed chimerism with a population of both host's and donor's erythrocytes, a period of the exclusive presence of donor's erythrocytes, and the resumed appearance of host's erythrocytes after eight months, with no signs of relapse of leukemia, were all observed by analysis of phenotypes. These isoenzymes served as a significant and practical genetic marker, which could be successfully used in studies on bone-marrow transplantation.

scholarly journals A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform

2021 ◽  
Vol 12 ◽  
Author(s):  
Hisanori Mayumi
Keyword(s):  
Bone Marrow ◽  
T Cells ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Marrow Cells ◽  
Mixed Chimerism ◽  
Post Transplantation ◽  
Clonal Deletion ◽  
Marrow Graft ◽  
Induced Tolerance

The bone marrow transplantation (BMT) between haplo-identical combinations (haploBMT) could cause unacceptable bone marrow graft rejection and graft-versus-host disease (GVHD). To cross such barriers, Johns Hopkins platform consisting of haploBMT followed by post-transplantation (PT) cyclophosphamide (Cy) has been used. Although the central mechanism of the Johns Hopkins regimen is Cy-induced tolerance with bone marrow cells (BMC) followed by Cy on days 3 and 4, the mechanisms of Cy-induced tolerance may not be well understood. Here, I review our studies in pursuing skin-tolerance from minor histocompatibility (H) antigen disparity to xenogeneic antigen disparity through fully allogeneic antigen disparity. To overcome fully allogeneic antigen barriers or xenogeneic barriers for skin grafting, pretreatment of the recipients with monoclonal antibodies (mAb) against T cells before cell injection was required. In the cells-followed-by-Cy system providing successful skin tolerance, five mechanisms were identified using the correlation between super-antigens and T-cell receptor (TCR) Vβ segments mainly in the H-2-identical murine combinations. Those consist of: 1) clonal destruction of antigen-stimulated-thus-proliferating mature T cells with Cy; 2) peripheral clonal deletion associated with immediate peripheral chimerism; 3) intrathymic clonal deletion associated with intrathymic chimerism; 4) delayed generation of suppressor T (Ts) cells; and 5) delayed generation of clonal anergy. These five mechanisms are insufficient to induce tolerance when the donor-recipient combinations are disparate in MHC antigens plus minor H antigens as is seen in haploBMT. Clonal destruction is incomplete when the antigenic disparity is too strong to establish intrathymic mixed chimerism. Although this incomplete clonal destruction leaves the less-proliferative, antigen-stimulated T cells behind, these cells may confer graft-versus-leukemia (GVL) effects after haploBMT/PTCy.

scholarly journals Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation

Blood ◽  
1987 ◽  
Vol 69 (4) ◽  
pp. 1262-1264 ◽  
Author(s):  
G Gahrton ◽  
S Tura ◽  
M Flesch ◽  
A Gratwohl ◽  
P Gravett ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Structure ◽  
Allogeneic Bone ◽  
Marrow Graft ◽  
Osteolytic Lesions ◽  
X Ray ◽  
Minor Improvement

Of 14 patients who received an allogeneic bone marrow graft from HLA- compatible sibling donors, 10 have survived for 6 to 34 months posttransplantation (median, 12 months). Four patients have died, two of relapse at extramedullary sites, one of severe acute GVHD, and one from GI bleeding and pericardial effusion. One patient is alive in relapse and four patients have signs of minimal persistent disease. Five patients are well without signs of active disease. Minor improvement in osteolytic lesions on X-ray were seen in three patients, but the X-ray bone structure was mainly unchanged in most patients. Bone marrow transplantation appears promising for treatment of certain patients with multiple myeloma.

scholarly journals Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation

Blood ◽  
1987 ◽  
Vol 69 (4) ◽  
pp. 1262-1264 ◽  
Author(s):  
G Gahrton ◽  
S Tura ◽  
M Flesch ◽  
A Gratwohl ◽  
P Gravett ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Structure ◽  
Allogeneic Bone ◽  
Marrow Graft ◽  
Osteolytic Lesions ◽  
X Ray ◽  
Minor Improvement

Abstract Of 14 patients who received an allogeneic bone marrow graft from HLA- compatible sibling donors, 10 have survived for 6 to 34 months posttransplantation (median, 12 months). Four patients have died, two of relapse at extramedullary sites, one of severe acute GVHD, and one from GI bleeding and pericardial effusion. One patient is alive in relapse and four patients have signs of minimal persistent disease. Five patients are well without signs of active disease. Minor improvement in osteolytic lesions on X-ray were seen in three patients, but the X-ray bone structure was mainly unchanged in most patients. Bone marrow transplantation appears promising for treatment of certain patients with multiple myeloma.

Sign in / Sign up

Export Citation Format

Share Document